Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018

High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease

(2018) Felipe Batalini et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone

(2018) Nelson Leung et al.   HAEMATOLOGICA

Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era

(2018) Arnt V. Kristen et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis

(2018) Duncan B. Richards et al.   Science Translational Medicine

Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone

(2018) Nelson Leung et al.   HAEMATOLOGICA

Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up

(2017) Ute Hegenbart et al.   HAEMATOLOGICA

Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response

(2017) Martha Grogan et al.   HEART

Heart transplantation in cardiac amyloidosis

(2017) Matthew Sousa et al.   HEART FAILURE REVIEWS

Diagnosis and management of neuropathies associated with plasma cell dyscrasias

(2017) Evan Rosenbaum et al.   HEMATOLOGICAL ONCOLOGY

Transthyretin familial amyloid polyneuropathy: an update

(2017) Violaine Plante-Bordeneuve   JOURNAL OF NEUROLOGY

Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis

(2017) Taxiarchis V. Kourelis et al.   MAYO CLINIC PROCEEDINGS

Prevalence of Monoclonal Gammopathy in Wild-Type Transthyretin Amyloidosis

(2017) Hallie I. Geller et al.   MAYO CLINIC PROCEEDINGS

Total Artificial Heart Implantation as a Bridge to Heart Transplantation in an Active Duty Service Member With Amyloid Cardiomyopathy

(2017) Michael S. Scully et al.   MILITARY MEDICINE

MALDI Mass Spectrometry Imaging: A Novel Tool for the Identification and Classification of Amyloidosis

(2017) Martin Winter et al.   PROTEOMICS

Role of Cardiac Magnetic Resonance in the Diagnosis and Prognosis of Nonischemic Cardiomyopathy

(2017) Amit R. Patel et al.   JACC-Cardiovascular Imaging

Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib

(2017) E Kastritis et al.   Blood Cancer Journal

Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis

(2017) A D Wechalekar et al.   Blood Cancer Journal

Importance of FISH genetics in light chain amyloidosis

(2017) Morie A. Gertz et al.   Oncotarget

Liver transplantation in transthyretin amyloidosis: Characteristics and management related to kidney disease

(2017) Ana Rocha et al.   Transplantation Reviews

Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up

(2017) Ute Hegenbart et al.   HAEMATOLOGICA

Transthyretin Cardiac Amyloidosis

(2017) Anit K. Mankad et al.   Current Cardiology Reports

Cardiac Amyloidosis as a Potential Confounder in Heart Failure With Preserved Ejection Fraction Trials

(2017) Erik B. Schelbert et al.   JACC-Heart Failure

Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid-directed monoclonal antibody

(2016) morie a. gertz et al.   AMERICAN JOURNAL OF HEMATOLOGY

Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial

(2016) V. Sanchorawala et al.   BLOOD

First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis

(2016) Taimur Sher et al.   BLOOD

Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis

(2016) Morie A. Gertz et al.   CANCER

Current and Future Treatment Approaches in Transthyretin Familial Amyloid Polyneuropathy

(2016) Philippe Kerschen et al.   Current Treatment Options in Neurology

First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction

(2016) Morie A. Gertz et al.   JOURNAL OF CLINICAL ONCOLOGY

Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category

(2016) E Muchtar et al.   LEUKEMIA

A More Accurate Approach to Amyloid Detection and Subtyping: Combining in situ Congo Red Staining and Immunohistochemistry

(2016) Thomas Menter et al.   PATHOBIOLOGY

Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium

(2015) Isabelle Lousada et al.   ADVANCES IN THERAPY

A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis

(2015) G. Palladini et al.   BLOOD

A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis

(2015) Maria T. Cibeira et al.   BRITISH JOURNAL OF HAEMATOLOGY

Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens

(2015) Tilmann Bochtler et al.   JOURNAL OF CLINICAL ONCOLOGY

The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation

(2015) Nelson Leung et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component

(2015) Duncan B. Richards et al.   NEW ENGLAND JOURNAL OF MEDICINE

Repurposing Diflunisal for Familial Amyloid Polyneuropathy

(2015) John L. Berk et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

FAP Neuropathy and Emerging Treatments

(2014) David Adams et al.   Current Neurology and Neuroscience Reports

Fatal Cardiac and Renal Allograft Rejection With Lenalidomide Therapy for Light-Chain Amyloidosis

(2013) D. E. Meyers et al.   AMERICAN JOURNAL OF TRANSPLANTATION

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis

(2013) A. D. Wechalekar et al.   BLOOD

Systemic Amyloidosis in England: an epidemiological study

(2013) Jennifer H. Pinney et al.   BRITISH JOURNAL OF HAEMATOLOGY

Paraneoplastic neuropathies

(2013) Francesc Graus et al.   CURRENT OPINION IN NEUROLOGY

Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach

(2013) G. Palladini et al.   HAEMATOLOGICA

Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis

(2013) Taxiarchis V. Kourelis et al.   JOURNAL OF CLINICAL ONCOLOGY

Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study

(2012) Laura Obici et al.   AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS

Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis

(2012) J. R. Mikhael et al.   BLOOD

Cdc42 regulates neutrophil migration via crosstalk between WASp, CD11b, and microtubules

(2012) S. Kumar et al.   BLOOD

A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis

(2012) E. Kastritis et al.   BLOOD

Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis

(2012) A. Dispenzieri et al.   BLOOD

Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis

(2012) M A Gertz et al.   BONE MARROW TRANSPLANTATION

Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis

(2012) Stefan Cordes et al.   CANCER

Relationship between monoclonal gammopathy and cardiac amyloid type

(2012) Joseph J. Maleszewski et al.   CARDIOVASCULAR PATHOLOGY

Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements

(2012) Shaji Kumar et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis

(2012) H Landau et al.   LEUKEMIA

Amyloid detection and typing: summary of current practice and recommendations of the consensus group

(2011) M. M. Picken et al.   AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS

Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis

(2011) J. E. Ward et al.   BLOOD

Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue

(2011) F. Brambilla et al.   BLOOD

Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs

(2010) Angela Dispenzieri et al.   AMERICAN JOURNAL OF HEMATOLOGY

Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis

(2010) U. Tapan et al.   BLOOD

Synergy of combined Doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models

(2010) Isabel Cardoso et al.   Journal of Translational Medicine

Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation inalpha2‐macroglobulinandtau: A population‐based autopsy study

(2008) Maarit Tanskanen et al.   ANNALS OF MEDICINE

Classification of amyloid deposits in diagnostic cardiac specimens by immunofluorescence

(2008) A. Bernard Collins et al.   CARDIOVASCULAR PATHOLOGY